Sodium-glucose cotransporter 2 inhibitors and atherosclerosis.

In the DELIVER trial, enrolling 57 % of patients with ASCVD, the composite outcome of worsening HF and CV death showed a 22 % reduction, though the reduction in CV alone did not reach statistical significance [ 72 ].

also in 111,027 other papers